Switch to:
Also traded in: UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
MDGN's Cash to Debt is ranked higher than
87% of the 941 Companies
in the Global Biotechnology industry.

( Industry Median: 45.46 vs. MDGN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MDGN' s Cash to Debt Range Over the Past 10 Years
Min: 0.24  Med: 10000.00 Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: 24.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -137.69
MDGN's ROE (%) is ranked lower than
88% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -32.22 vs. MDGN: -137.69 )
Ranked among companies with meaningful ROE (%) only.
MDGN' s ROE (%) Range Over the Past 10 Years
Min: -611.28  Med: -131.63 Max: -76.67
Current: -137.69
-611.28
-76.67
ROA (%) -117.46
MDGN's ROA (%) is ranked lower than
89% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. MDGN: -117.46 )
Ranked among companies with meaningful ROA (%) only.
MDGN' s ROA (%) Range Over the Past 10 Years
Min: -307.78  Med: -134.40 Max: -64.26
Current: -117.46
-307.78
-64.26
ROC (Joel Greenblatt) (%) -8640.93
MDGN's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. MDGN: -8640.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDGN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8260.07  Med: -2769.79 Max: -1211.5
Current: -8640.93
-8260.07
-1211.5
EBITDA Growth (3Y)(%) 7.50
MDGN's EBITDA Growth (3Y)(%) is ranked higher than
65% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. MDGN: 7.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MDGN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 1.7  Med: 7.50 Max: 215.6
Current: 7.5
1.7
215.6
EPS Growth (3Y)(%) 1.20
MDGN's EPS Growth (3Y)(%) is ranked higher than
58% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -5.20 vs. MDGN: 1.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MDGN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 1.20 Max: 233.1
Current: 1.2
0
233.1
» MDGN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

MDGN Guru Trades in

Q1 2015

MDGN Guru Trades in Q1 2015

Jim Simons 25,200 sh (New)
» More
Q2 2015

MDGN Guru Trades in Q2 2015

Jim Simons 43,408 sh (+72.25%)
» More
Q3 2015

MDGN Guru Trades in Q3 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:IDRA, NAS:OSIR, NAS:QURE, NAS:ABUS, NAS:ENZY, NAS:CBMG, NAS:FOMX, AMEX:PFNX, NAS:MDWD, OTCPK:SPHRY, NAS:CMRX, AMEX:AMPE, OTCPK:BBLG, NAS:BOLT, OTCPK:CTIX, NAS:CDXS, NAS:ITEK, NAS:NVIV, NAS:FLKS, NAS:IMDZ » details
Traded in other countries:MEDU.UK,
Medgenics Inc is a medical technology and therapeutics company. The Company along with its subsidiaries is engaged in the research and development of products in the field of biotechnology and associated medical equipment.

Medgenics Inc was incorporated on January 27, 2000 in Delaware. The Company is a medical technology and therapeutics company. The Company along with its subsidiaries is engaged in the research and development of products in the field of biotechnology and associated medical equipment. The Company has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue. The Company has also developed an Interferon Alpha secreting Biopump for the treatment of viral Hepatitis. The Company's Transduced Autologous Restorative Gene Therapy converts a small piece of the patient's own dermal skin tissue into a protein. Its proprietary device, the DermaVac, is used to extract a small piece of tissue via a form of needle biopsy from the skin's lower level - the dermis - of patient under local anesthesia. Its EPODURE Biopump is designed to provide a safer, more reliable, and more cost-effective anemia therapy. The Company faces competition within protein/peptide therapeutics, directly from established competitors using alternative protein manufacturing and delivery methods for EPO and in many orphan and rare disease areas respectively. The Company's production, distribution, and marketing of products employing its technology, and its development activities, are subject to various governmental regulations in the United States and in other countries. In the United States, its products are regulated as biologics and medical devices and are subject to the Federal Food, Drug, and Cosmetic Act, as amended, and the regulations of the FDA, as well as to other federal, state, and local statutes and regulations.

Ratios

vs
industry
vs
history
P/B 4.39
MDGN's P/B is ranked lower than
62% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. MDGN: 4.39 )
Ranked among companies with meaningful P/B only.
MDGN' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 30.2
Current: 4.39
0
30.2
Current Ratio 12.57
MDGN's Current Ratio is ranked higher than
82% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. MDGN: 12.57 )
Ranked among companies with meaningful Current Ratio only.
MDGN' s Current Ratio Range Over the Past 10 Years
Min: 0.24  Med: 6.45 Max: 18.08
Current: 12.57
0.24
18.08
Quick Ratio 12.57
MDGN's Quick Ratio is ranked higher than
82% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: 4.21 vs. MDGN: 12.57 )
Ranked among companies with meaningful Quick Ratio only.
MDGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.24  Med: 6.45 Max: 18.08
Current: 12.57
0.24
18.08

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.55
MDGN's Price/Net Cash is ranked higher than
58% of the 504 Companies
in the Global Biotechnology industry.

( Industry Median: 5.38 vs. MDGN: 4.55 )
Ranked among companies with meaningful Price/Net Cash only.
MDGN' s Price/Net Cash Range Over the Past 10 Years
Min: 2.86  Med: 8.80 Max: 148.8
Current: 4.55
2.86
148.8
Price/Net Current Asset Value 4.44
MDGN's Price/Net Current Asset Value is ranked higher than
56% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 5.07 vs. MDGN: 4.44 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDGN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.66  Med: 8.37 Max: 74.4
Current: 4.44
2.66
74.4
Price/Tangible Book 4.41
MDGN's Price/Tangible Book is ranked lower than
53% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 3.99 vs. MDGN: 4.41 )
Ranked among companies with meaningful Price/Tangible Book only.
MDGN' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.59  Med: 7.88 Max: 95.82
Current: 4.41
2.59
95.82
Earnings Yield (Greenblatt) (%) -29.09
MDGN's Earnings Yield (Greenblatt) (%) is ranked lower than
76% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. MDGN: -29.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDGN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -44.4  Med: 0.00 Max: 0
Current: -29.09
-44.4
0

More Statistics

EPS (TTM) $ -1.48
Beta0.55
Short Percentage of Float4.90%
52-Week Range $3.09 - 10.25
Shares Outstanding (Mil)33.21
» More Articles for MDGN

Headlines

Articles On GuruFocus.com
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 

More From Other Websites
MEDGENICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jun 24 2016
$20M stock sale: Gene therapy company raising funds for rare disease treatments Jun 22 2016
Why Are These Stocks Deep in Red Today? Jun 21 2016
Medgenics Announces Pricing of Secondary Offering Jun 21 2016
Medgenics Announces Pricing of Public Offering of Common Stock Jun 21 2016
Medgenics Announces Pricing of Public Offering of Common Stock Jun 21 2016
Medgenics Announces Public Offering of Common Stock Jun 20 2016
Medgenics Announces Public Offering of Common Stock Jun 20 2016
MEDGENICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Jun 17 2016
Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents... Jun 17 2016
Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents... Jun 17 2016
Medgenics to Present at the JMP Life Sciences Conference Jun 15 2016
Medgenics to Present at the JMP Life Sciences Conference Jun 15 2016
MDGN Adds Another High-Potential Orphan Candidate Jun 07 2016
Medgenics, Inc. :MDGN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 6, 2016 Jun 06 2016
Medgenics, CHOP & Japanese biopharm firm team up to take on rare pediatric disease Jun 06 2016
Medgenics Obtains Rights to First-in-Class Biologic for Severe Pediatric Onset IBD Jun 06 2016
MEDGENICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Jun 06 2016
Medgenics Obtains Rights to First-in-Class Biologic for Severe Pediatric Onset IBD Jun 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)